Reduced Phosphocholine and Hyperpolarized Lactate Provide Magnetic Resonance Biomarkers of Pi3k/akt/mtor Inhibition in Glioblastoma Neuro-onco Lo Gy

The phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway is activated in more than88% of glioblastomas (GBM). New drugs targeting this pathway are currently in clinical trials. However, noninvasive assessment of treatment response remains challenging. By using magnetic resonance spectroscopy (MRS), PI3K/Akt/mTOR pathway inhibition was monitored in 3 GBM cell lines (GS-2, GBM8, and GBM6; each with a distinct pathway activating mutation) through the measurement of 2 mechanistically linked MR biomarkers: phosphocholine (PC) and hyperpolarized lactate.(31)P MRS studies showed that treatment with the PI3K inhibitor LY294002 induced significant decreases in PC to 34 %± 9% of control in GS-2 cells, 48% ± 5% in GBM8, and 45% ± 4% in GBM6. The mTOR inhibitor everolimus also induced a significant decrease in PC to 62% ± 14%, 57% ± 1%, and 58% ± 1% in GS-2, GBM8, and GBM6 cells, respectively. Using hyperpolarized (13)C MRS, we demonstrated that hyperpolarized lactate levels were significantly decreased following PI3K/Akt/mTOR pathway inhibition in all 3 cell lines to 51% ± 10%, 62% ± 3%, and 58% ± 2% of control with LY294002 and 72% ± 3%, 61% ± 2%, and 66% ± 3% of control with everolimus in GS-2, GBM8, and GBM6 cells, respectively. These effects were mediated by decreases in the activity and expression of choline kinase α and lactate dehydrogenase, which respectively control PC and lactate production downstream of HIF-1. Treatment with the DNA damaging agent temozolomide did not have an effect on either biomarker in any cell line. This study highlights the potential of PC and hyperpolarized lactate as noninvasive MR biomarkers of response to targeted inhibitors in GBM.

[1]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[2]  Kristen Scott,et al.  Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma , 2012, NeuroImage.

[3]  C. James,et al.  Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging , 2011, Journal of magnetic resonance imaging : JMRI.

[4]  S. Takekoshi,et al.  Analysis of mTOR Inhibition-Involved Pathway in Ovarian Clear Cell Adenocarcinoma , 2011, Acta histochemica et cytochemica.

[5]  James B. Mitchell,et al.  Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1‐13C]pyruvate and 13C magnetic resonance spectroscopic imaging , 2011, Magnetic resonance in medicine.

[6]  S. Ronen,et al.  17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 , 2010, Breast Cancer Research.

[7]  Simon Hu,et al.  Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. , 2010, Cancer research.

[8]  Albert P. Chen,et al.  Implementation of 3 T Lactate-Edited 3D 1H MR Spectroscopic Imaging with Flyback Echo-Planar Readout for Gliomas Patients , 2010, Annals of Biomedical Engineering.

[9]  M. Leach,et al.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. , 2010, Cancer research.

[10]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[11]  B. Hemmings,et al.  Deregulated signalling networks in human brain tumours. , 2010, Biochimica et biophysica acta.

[12]  Susan M. Chang,et al.  Recent advances in therapy for glioblastoma. , 2010, Archives of neurology.

[13]  John Kurhanewicz,et al.  Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Cancer research.

[14]  Ilwoo Park,et al.  Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. , 2010, Neuro-oncology.

[15]  C. James,et al.  Hyperpolarized 13 C MR Metabolic Imaging Provides an Early Biomarker of MGMT Activity and Response to Temozolomide Treatment , 2010 .

[16]  M. Leach,et al.  Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR , 2009, NMR in biomedicine.

[17]  A. Heerschap,et al.  Efficient 1H to 31P polarization transfer on a clinical 3T MR system , 2008, Magnetic resonance in medicine.

[18]  Albert P. Chen,et al.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. , 2008, Cancer research.

[19]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[20]  C. James,et al.  PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel , 2008, Clinical Cancer Research.

[21]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[22]  M. Westphal,et al.  Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria , 2008, Oncogene.

[23]  F. Vesuna,et al.  Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. , 2008, Cancer research.

[24]  G. Mills,et al.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. , 2008, Cancer research.

[25]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[26]  S J Kohler,et al.  In vivo 13carbon metabolic imaging at 3T with hyperpolarized 13C‐1‐pyruvate , 2007, Magnetic resonance in medicine.

[27]  C. James,et al.  Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.

[28]  C. Billottet,et al.  A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.

[29]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[30]  Paul Workman,et al.  Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[31]  R. Gillies,et al.  Metabolite changes in HT‐29 xenograft tumors following HIF‐1α inhibition with PX‐478 as studied by MR spectroscopy in vivo and ex vivo , 2005, NMR in biomedicine.

[32]  S. Canevari,et al.  Alterations of choline phospholipid metabolism in ovarian tumor progression. , 2005, Cancer research.

[33]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Nelson.  Multivoxel magnetic resonance spectroscopy of brain tumors. , 2003, Molecular cancer therapeutics.

[35]  S. Nelson.  Multivoxel magnetic resonance spectroscopy of brain tumors. , 2003, Molecular cancer therapeutics.

[36]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[37]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[38]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[39]  Susan M. Chang,et al.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. , 2001, Magnetic resonance imaging.

[40]  Leo L. Cheng,et al.  Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. , 2000, Neuro-oncology.

[41]  R. Gillies,et al.  Applications of magnetic resonance in model systems: cancer therapeutics. , 2000, Neoplasia.

[42]  I. Gribbestad,et al.  Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy , 1999, Journal of magnetic resonance imaging : JMRI.

[43]  T. Powles,et al.  Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.

[44]  Z. Bhujwalla,et al.  Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. , 1996, International journal of radiation oncology, biology, physics.

[45]  B. Ebert,et al.  Hypoxic Regulation of Lactate Dehydrogenase A , 1995, The Journal of Biological Chemistry.

[46]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[47]  F Podo,et al.  In vivo 31P MRS of experimental tumours , 1993, NMR in biomedicine.

[48]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[49]  H. Degani,et al.  Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. , 1991, Biochimica et biophysica acta.

[50]  Steven J. Steindel,et al.  4 Lactate Dehydrogenase , 1975 .

[51]  Hans Ulrich Bergmeyer,et al.  Methods of Enzymatic Analysis , 2019 .